Clinical trial data for TKIs in ALK-rearranged NSCLC

Clinical trial data for TKIs in ALK-rearranged NSCLC

User Photo
VJOncology

1 year
229 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the efficacy of different tyrosine kinase inhibitors (TKIs) on ALK-rearranged non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.
Up Next Autoplay